Works in Investigational New Drugs, 2018, Vol 36, Issue 5

Results: 25
    1

    Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 927, doi. 10.1007/s10637-018-0631-8
    By:
    • Pasini, Felice;
    • Barile, Carmen;
    • Caruso, Donatella;
    • Modena, Yasmina;
    • Fraccon, Anna Paola;
    • Bertolaso, Laura;
    • Menon, Daniela;
    • La Russa, Francesca;
    • Crepaldi, Giorgio;
    • Bononi, Antonio;
    • Spezzano, Roberto;
    • Padrini, Roberto;
    • Corona, Giuseppe;
    • Gusella, Milena
    Publication type:
    Article
    2

    Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 919, doi. 10.1007/s10637-018-0630-9
    By:
    • Monk, Paul;
    • Liu, Glenn;
    • Stadler, Walter M.;
    • Geyer, Susan;
    • Huang, Ying;
    • Wright, John;
    • Villalona-Calero, Miguel;
    • Wade, James;
    • Szmulewitz, Russell;
    • Gupta, Shilpa;
    • Mortazavi, Amir;
    • Dreicer, Robert;
    • Pili, Roberto;
    • Dawson, Nancy;
    • George, Saby;
    • Garcia, Jorge A.
    Publication type:
    Article
    3
    4

    Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 903, doi. 10.1007/s10637-018-0617-6
    By:
    • Nakao, Akira;
    • Uchino, Junji;
    • Igata, Fumiyasu;
    • On, Rintaro;
    • Ikeda, Takato;
    • Yatsugi, Hiroshi;
    • Hirano, Ryosuke;
    • Sasaki, Tomoya;
    • Tanimura, Keiko;
    • Imabayashi, Tatsuya;
    • Tamiya, Nobuyo;
    • Kaneko, Yoshiko;
    • Yamada, Tadaaki;
    • Nagata, Nobuhiko;
    • Watanabe, Kentaro;
    • Kishimoto, Junji;
    • Takayama, Koichi;
    • Fujita, Masaki
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12

    The concomitant use of lapatinib and paracetamol - the risk of interaction.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 819, doi. 10.1007/s10637-018-0573-1
    By:
    • Karbownik, Agnieszka;
    • Szałek, Edyta;
    • Sobańska, Katarzyna;
    • Grabowski, Tomasz;
    • Klupczynska, Agnieszka;
    • Plewa, Szymon;
    • Wolc, Anna;
    • Magiera, Magdalena;
    • Porażka, Joanna;
    • Kokot, Zenon J.;
    • Grześkowiak, Edmund
    Publication type:
    Article
    13
    14
    15

    Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 797, doi. 10.1007/s10637-018-0569-x
    By:
    • Oerlemans, Ruud;
    • Berkers, Celia R.;
    • Assaraf, Yehuda G.;
    • Scheffer, George L.;
    • Peters, Godefridus J.;
    • Verbrugge, Sue Ellen;
    • Cloos, Jacqueline;
    • Slootstra, Jerry;
    • Meloen, Rob H.;
    • Shoemaker, Robert H.;
    • Dijkmans, Ben A. C.;
    • Scheper, Rik J.;
    • Ovaa, Huib;
    • Jansen, Gerrit
    Publication type:
    Article
    16
    17
    18

    SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 773, doi. 10.1007/s10637-018-0566-0
    By:
    • Koukourakis, Michael I.;
    • Giatromanolaki, Alexandra;
    • Fylaktakidou, Konstantina;
    • Sivridis, Efthimios;
    • Zois, Christos E.;
    • Kalamida, Dimitra;
    • Mitrakas, Achilleas;
    • Pouliliou, Stamatia;
    • Karagounis, Ilias V.;
    • Simopoulos, Konstantinos;
    • Ferguson, David J. P.;
    • Harris, Adrian L.
    Publication type:
    Article
    19
    20

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 848, doi. 10.1007/s10637-018-0562-4
    By:
    • Schneeweiss, Andreas;
    • Park-Simon, Tjoung-Won;
    • Albanell, Joan;
    • Lassen, Ulrik;
    • Cortés, Javier;
    • Dieras, Veronique;
    • May, Marcus;
    • Schindler, Christoph;
    • Marmé, Frederik;
    • Cejalvo, Juan Miguel;
    • Martinez-Garcia, Maria;
    • Gonzalez, Iria;
    • Lopez-Martin, Jose;
    • Welt, Anja;
    • Levy, Christelle;
    • Joly, Florence;
    • Michielin, Francesca;
    • Jacob, Wolfgang;
    • Adessi, Céline;
    • Moisan, Annie
    Publication type:
    Article
    21
    22
    23
    24

    A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 5, p. 828, doi. 10.1007/s10637-017-0551-z
    By:
    • van der Biessen, Diane A. J.;
    • Gietema, Jourik A.;
    • de Jonge, Maja J. A.;
    • Desar, Ingrid M. E.;
    • den Hollander, Martha W.;
    • Dudley, Matthew;
    • Dunbar, Martin;
    • Hetman, Robert;
    • Serpenti, Camille;
    • Xiong, Hao;
    • Mittapalli, Rajendar K.;
    • Timms, Kirsten M.;
    • Ansell, Peter;
    • Ratajczak, Christine K.;
    • Shepherd, Stacie Peacock;
    • van Herpen, Carla M. L.
    Publication type:
    Article
    25